GALT — what changed in the latest 10-Q
A section-by-section comparison of GALT's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-15 vs the prior 10-Q · 2025-11-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +21 | −18 | ~20 | 28 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | +3 | 0 | ~2 | 1 |
| Risk factors | Text added/removed | 0 | 0 | ~1 | 0 |
| Other information | Text added/removed | 0 | 0 | ~1 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-15
our NAVIGATE trial was our only active clinical trial, and we currently do not have plans or funding to undertake another clinical trial;
we have from time to time faced substantial doubt about our ability to continue as a going concern;
we have incurred significant operating losses since our inception and cannot assure you that we will generate revenue or profit;
we may be unable to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates;
uncertainties related to our technology and clinical trials, including expected dates of availability of clinical data;
Text removed vs the prior filing · source: 10-Q · 2025-11-14
we have incurred significant operating losses since our inception and cannot assure you that we will generate revenue or profit,
we may be unable to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates,
uncertainties related to our technology and clinical trials, including expected dates of availability of clinical data,
we may be unable to demonstrate the efficacy and safety of our developmental product candidates in human trials,
we may be unable to improve upon, protect and/or enforce our intellectual property,
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-15
As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, we identified a material weakness in our internal control over financial reporting. Specifically, we did not implement and maintain effective controls related to the valuation of derivative liabilities as…
In an effort to address the identified material weakness and enhance our internal controls related to our valuation of derivative liabilities process, we continue to maintain our financial reporting process we followed to prepare consolidated financial statements in accordance with GAAP for audit co…
Notwithstanding the material weakness, our management has concluded that the consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformit…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice